Medicare drug price negotiations will shrink the focus of R&D pursuits, says Dr. Scott Gottlieb

Dr. Scott Gottlieb, a former FDA commissioner and also serves on the boards of Pfizer and Illumina, joins 'The Exchange' to discuss the inflation reduction act creating an avenue for medicare to directly negotiate prices with pharmaceutical companies, the unintended consequences of price regulation on drug development, and what ten prescription drugs are first to be considered.